Autolus Therapeutics (AUTL) Gross Margin (2024 - 2025)
Autolus Therapeutics (AUTL) posted quarterly Gross Margin of 4.29% for Q4 2025, up 3916123.0% year-on-year from N/an in Q4 2024, and up 87.81% on a QoQ basis from 35.15% in Q3 2025.
Autolus Therapeutics (AUTL) Gross Margin (2024 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported Gross Margin for 2 consecutive years, with 4.29% the latest figure, recorded in Q4 2025.
- Quarterly Gross Margin rose 3916123.0% year-over-year to 4.29% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 27.83% (down 1541.0% YoY) and the FY2025 annual result came in at 27.83%, down 1531.0% from the prior year.
- Gross Margin grew to 4.29% in Q4 2025 per AUTL's latest filing, from 35.15% in the prior quarter.
- Over the last five years, Gross Margin for AUTL reached as high as 100.0% in Q1 2024 and fell as low as 39165.52% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Autolus Therapeutics | 404.53 Mn | 103.82 Mn | -1.04 Mn | -4.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.29% |
| Sep 30, 2025 | -35.15% |
| Jun 30, 2025 | -16.83% |
| Mar 31, 2025 | -99.86% |
| Dec 31, 2024 | -39,165.52% |
| Mar 31, 2024 | 100.00% |